A Cancer Immunotherapy Company Harnessing the Human Immune System To Diagnose and Treat Cancer January 2015 January 2015 1
Disclaimer Disclaimer Forward Looking Statements THIS PRESENTATION CONTAINS FORWARD ‐ LOOKING STATEMENTS AND PROJECTIONS. THE COMPANY MAKES NO EXPRESS OR IMPLIED REPRESENTATION OR WARRANTY AS TO THE COMPLETENESS OF THIS INFORMATION OR, IN THE CASE OF THE PROJECTIONS, AS TO THEIR ATTAINABILITY OR THE ACCURACY AND COMPLETENESS OF THE ASSUMPTIONS FROM WHICH THEY ARE DERIVED, AND IT IS EXPECTED THAT EACH PROSPECTIVE INVESTOR WILL PURSUE HIS, HER, OR ITS OWN INDEPENDENT INVESTIGATION IT MUST BE RECOGNIZED THAT ESTIMATES OF THE COMPANY’S PERFORMANCE ARE NECESSARILY SUBJECT TO A INVESTIGATION. IT MUST BE RECOGNIZED THAT ESTIMATES OF THE COMPANY S PERFORMANCE ARE NECESSARILY SUBJECT TO A HIGH DEGREE OF UNCERTAINTY AND MAY VARY MATERIALLY FROM ACTUAL RESULTS. IN PARTICULAR, THIS PRESENTATION CONTAINS STATEMENTS, INCLUDING WITHOUT LIMITATION THE PROJECTIONS, THAT CONSTITUTE “FORWARD ‐ LOOKING STATEMENTS” WITHIN THE MEANING OF THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995. THESE STATEMENTS APPEAR IN A NUMBER OF PLACES IN THIS PRESENTATION AND INCLUDE, BUT ARE NOT LIMITED TO, STATEMENTS REGARDING THE COMPANY’S PLANS, INTENTIONS, BELIEFS, EXPECTATIONS AND ASSUMPTIONS, AS WELL AS OTHER STATEMENTS THAT ARE NOT NECESSARILY HISTORICAL FACTS. THE COMPANY COMMONLY USES WORDS IN THIS MEMORANDUM SUCH AS “ANTICIPATES,” “BELIEVES,” “PLANS,” “EXPECTS,” “FUTURE,” “INTENDS,” AND SIMILAR EXPRESSIONS TO IDENTIFY FORWARD ‐ LOOKING STATEMENTS AND PROJECTIONS. YOU ARE CAUTIONED THAT THESE FORWARD ‐ LOOKING STATEMENTS AND PROJECTIONS ARE NOT GUARANTEES OF FUTURE PERFORMANCE AND INVOLVE RISKS AND UNCERTAINTIES. THE COMPANY’S ACTUAL RESULTS MAY DIFFER MATERIALLY FROM THOSE IN THE FORWARD ‐ LOOKING STATEMENTS AND PROJECTIONS DUE TO VARIOUS FACTORS, INCLUDING COMPETITION MARKET FACTORS GENERAL ECONOMIC CONDITIONS AND THOSE DESCRIBED IN THE “RISK FACTORS” INCLUDING COMPETITION, MARKET FACTORS, GENERAL ECONOMIC CONDITIONS AND THOSE DESCRIBED IN THE “RISK FACTORS” SECTION. THE INFORMATION CONTAINED IN THIS PRESENTATION DESCRIBES SEVERAL, BUT NOT NECESSARILY ALL, IMPORTANT FACTORS THAT COULD CAUSE THESE DIFFERENCES. 2
Differentiated Cancer Immunotherapy Company I th C • Advancing two unique and complementary oncology ‐ focused immunotherapy t technologies each with multiple products with near term inflection points h l i h ith lti l d t ith t i fl ti i t – Intersection is the intact human immune system – Antibody discovery platform leverages vaccine program in clinical trials • • Cancer vaccine program backed by NIH funding Cancer vaccine program backed by NIH funding – In ‐ licensed portfolio of therapeutic cancer vaccines from Memorial Sloan ‐ Kettering Cancer Center – Two vaccines (sarcoma and ovarian cancer) in late Phase 2 POC with 2016 readout – Neuroblastoma vaccine received Orphan Drug Designation; on track to enter Phase 2 in 2015 p g g • Antibody discovery platform with >100 fully ‐ human antibody leads – Discovered novel human antibodies from blood samples of patients vaccinated with the licensed vaccines – Lead antibody program, HuMab 5B1, targeting metastatic pancreatic cancer, to enter Phase 1 in 2H2015 with early data readout by year end for diagnostic and therapeutic indications • Capital efficient development model • • Experienced management and board with significant public company experience Experienced management and board with significant public company experience 3
Capital Efficient Business Model p Operate as virtual company in all areas but discovery (14 FTEs) • • Focus on discovery and early development where resource requirements are less intensive • Develop products to earliest proof of concept and then partner p p p p p • No discovery or early development costs for vaccine program – Discovery and early development completed at MSKCC at no expense to MabVax – Product transferred to MabVax at entry into Phase 2 Product transferred to MabVax at entry into Phase 2 • Plan is that each antibody candidate developed through Phase 1 • Early partnering objective to obtain additional capital and provide early returns to investors returns to investors • Preclinical antibody pipeline robust enough to support early partnering of first assets 4
Capital Efficient Business Significant Progress Since Becoming A Model Model Public Company In 2014 bli 2014 Series C financing raised $3M Common stock financing and warrant exercise raised $4.5M Merger/ name change/ reverse stock split/ ticker symbol change Strengthened Board of Directors with 4 new members Agreement with Juno Therapeutics and MSKCC on development of CAR T ‐ cell products Phase 2 of NIH award of $1.75M to develop 5B1 ‐ antibody based diagnostic h 2 f d f $ d l ib d b d di i product Orphan Drug Designation for childhood cancer ‐ neuroblastoma vaccine Initiated GMP manufacturing of lead antibody product candidate Initiated GMP manufacturing of lead antibody product candidate 5
Management and Board of Directors Management and Board of Directors Management Board of Directors J D J. David Hansen id H MabVax Avanir Xenerex MabVax, Avanir, Xenerex K Ken Cohen C h F Founder, Former President and CEO d F P id t d CEO Biosciences, Dura, Schering ‐ of Somaxon Pharmaceuticals, Founder, President & CEO Plough, Key, BMS Board Member Synbiotics, Canji Robert Hoffman Senior VP Finance & CFO of Arena Memorial Sloan Kettering Cancer Philip Livingston, Pharmaceuticals, CFO Polaris Group, Center M D M.D. Member FASB Advisory Committee Founder & Chief Science Officer Jeffery Ravetch, Rockefeller University, National Academy of Sciences and Institute Gregory Hanson Avanir, First Cornerstone, Brinson M.D., Ph.D Patrick Securities, Mast of Medicine, Academy of Arts and Chief Financial Officer Therapeutics, Xxsys Technologies, p y g Sciences and the American Sciences and the American L ‐ 3 Communications Association for Advancement of Science Avanir, Xenerex Biosciences, Wolfgang Scholz, Paul Maier Former CFO Seqenom Inc., Former Tanabe Research Laboratories Ph.D. Sr. VP & CFO Ligand USA, Desmos, Scripps Research Founder & Vice President Founder & Vice President Institute Institute Pharmaceuticals h i l Antibody Discovery Michael Wick, M.D., Telik. CV Therapeutics, Lederle Labs. Associate Professor Harvard Medical Ph.D. Paul Maffuid, Ph.D. AAIPharma Services, School. Biopharmalogics, Arena Vice President Product Pharmaceuticals, Amylin, Pharmaceuticals, Amylin, De elopment & Operations Development & Operations Philip Livingston, Corporate Officer Magellan Labs, Cabrillo Labs, Glaxo Research Institute M.D. J. David Hansen Corporate Officer 6
Robust Pipeline with Multiple Near ‐ Term Milestones l Partner Partner 2014 2015 2016 2014 2015 2016 Antibody Program Antibody Program Early Phase 1 Completion 5B1 Antibody PET Agent MSKCC/ Pancreatic Cancer Diagnostic Results YE2015 of Phase 1 NIH Completion Early Phase 1 Pancreatic & Colon Cancer 5B1 Therapeutic Antibody MSKCC/ Therapeutic Agent Results YE2015 of Phase 1 Gallus Pancreatic & Colon 5B1 Antibody Drug Conjugate 5B1 Antibody Drug Conjugate Heidelberg Heidelberg Preclinical Work Preclinical Work GMP Mfg. and Tox GMP Mfg. and Tox Cancer Therapeutic Pharma Vaccine Program Phase 2 Adjuvant Therapy to Prevent Recurrence and Prolong Survival MSKCC MSKCC Sarcoma Vaccine Sarcoma Vaccine OS Results OS Results Phase 2 POC Trial Phase 2 POC Trial 1H2016 Phase 2 NIH/GOG/ Adjuvant Therapy to Prevent Recurrence and Prolong Survival OS Results MSKCC Phase 2 POC Trial Ovarian Vaccine 1H2016 MSKCC/NIH Positive Phase 1 Initiate Phase 2 Vaccine Mfg. NANT/SKC Trial Completed Trial IND Neuroblastoma Vaccine 7
Clinically Advanced Cancer Vaccine P Program • Vaccines elicit an immune response against validated tumor antigens present on solid tumors • Two late stage Phase II clinical programs; sarcoma and ovarian cancer – All patients enrolled and vaccinated and minimal expense for survival follow ‐ up • Plan to pursue out ‐ licensing option for sarcoma and ovarian cancer vaccines after survival endpoint reached 2016 Neuroblastoma vaccine ready for Phase 2 trial initiation in 2H2015 • Childhood cancer with � 700 new cases per year and received US FDA as Orphan Drug Designation – – Phase 1 trial in neuroblastoma completed with strongly encouraging results on time to progression and survival • Broader portfolio includes completed early stage clinical trials in melanoma Broader portfolio includes completed early stage clinical trials in melanoma, neuroblastoma, sarcoma, breast cancer , ovarian cancer, and small cell lung cancer 8
Recommend
More recommend
